NRG Oncology has pulled together a webpage to collate COVID-19 information for patients as well as for our researchers and research staff at our sites.
Guidance for Shipment of CTEP Oral IND Agents (8/31/2020)
Resumption of Biospecimen Submissions for Breast and CRC Studies Memo (8/17/2020)
NCTN-Oral Agent Shipment Funding Info Sheet (7/27/2020)
Updated Protocol Deviation Memo & Log (7/10/2020)
CTEP Oral IND Agent Shipments Memo (6/2/2020)
Coming Soon: National Cancer Institute Natural History Study of COVID-19 in Cancer Patients (4/20/2020)
NRG Oncology Leadership Special Message Regarding COVID-19 (4/13/2020)
CIRB Information about COVID-19 (3/27/2020)
CIRB Remote Consent Procedures and Other FAQ’s (4/22/2020)
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic (7/2/2020)
Guidance for Collection of Adverse Events Related to COVID-19 Infection (3/25/2020)
Additional Guidance Regarding Alternative Procedures for Clinical Trials Supported by the NCI Cancer Therapy Evaluation Program (CTEP) and NCI Community Oncology Research Program (NCORP) Affected by the Spread of the Novel Coronavirus (3/23/2020)
NRG Oncology Leadership Special Message Regarding COVID-19 (3/23/2020)
Updated Interim Guidance for Patients on Clinical Trials Sponsored by the NCI Cancer Therapy Evaluation Programs: Shipment of Oral IND Agents to Clinical Trial Subjects (3/23/2020)
NRG Oncology Leadership Special Message Regarding COVID-19 (3/14/2020)
We understand that as a patient or family member of a patient participating in – or considering participatingin, a research study may have questions related to your care and/or ability to complete the requirements of the research study given the current pandemic. See also the information linked below for cancer patients from the National Cancer Institute.
Medical facilities are instituting changes in how they operate in response to local risk, local or state requirements, and types of essential activities carried out at that particular facility. You should always check in if you have questions or concerns, according to what your research physician or other representative of your medical facility has directed you to do.
Some potential changes that may occurfor clinical trial participants are highlighted below:
Also see guidance for Cancer Patients from the National Cancer Institute
NRG Oncology remains committed to supporting your research efforts, whatever that may look like at your institution today. While the pandemic is commanding time, energy, and resources across the country and the world right now, the conduct of clinical research is a long-term commitment. Together, we will weather this storm and do our best for patients, Member Sites, study teams, and staff - and get to those research outcomes as best we can.
Protocol-specific guidance will be provided through the CTSU as always, and disseminated through our weekly broadcast or more frequently as required. This webpage links to the current guidance we are following from the NCI and CIRB. Come back often real-time updates will be posted here.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.